Allogene疗法(ALLO)
4.925 -0.125 -2.4752%
| 今开：4.99 | 昨收：5.05 |
| 最高：5.05 | 最低：4.905 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：7.11649611E8 |
Allogene疗法的热门评论
持股变动声明
Allogene疗法(ALLO)2022-06-23 04:51
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001214659-22-008241 Size: 4 KB 网页链接查看全文
持股变动声明
Allogene疗法(ALLO)2022-06-18 05:03
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001214659-22-008172 Size: 4 KB 网页链接查看全文
持股变动声明
Allogene疗法(ALLO)2022-06-18 05:03
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001214659-22-008170 Size: 4 KB 网页链接查看全文
![[为什么]](http://js.xueqiu.com/ugc/images/face/emoji_14_doubt.png "[为什么]"){kind=small}
持股变动声明
Allogene疗法(ALLO)2022-05-20 05:48
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001214659-22-007226 Size: 5 KB 网页链接查看全文
禅禅流水2021-01-17 10:33
我这个小帖子引起了较大的关注。为了避免误导，我周末又查了一些资料，用Allogene的BCMA靶点通用CAR-T打个补丁：Allogene公司的通用CAR-T产品ALLO-715。
该临床产品针对MM和其他BCMA阳性癌症。它利用Cellectis的TALEN基因编辑技术特异性破坏T细胞受体α链和CD52基因座，经修饰过的细胞具有较低...查看全文
禅禅流水2021-01-18 20:29
ASH 2020| BCMA靶点开发：CAR-T、双抗、抗体偶联药物谁将率先胜出？网页链接
ASH2020会议似乎形成了一个共识：在多发性骨髓瘤领域，细胞疗法通常比双特异性抗体药物更有效，而双特异性药物比抗体药物偶联物更有效。
$金斯瑞生物科技(01548)$ $传...查看全文
当期报告
Allogene疗法(ALLO)2022-05-05 04:18
$Allogene疗法(ALLO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001737287-22-000033 Act: 34 Size: 236 KB 网页链接查看全文
季度财报
Allogene疗法(ALLO)2022-05-05 04:27
$Allogene疗法(ALLO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001737287-22-000035 Act: 34 Size: 6 MB 网页链接查看全文
Allogene疗法的最新评论
持股变动声明
Allogene疗法(ALLO)03-17 05:36
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001737287-23-000025 Size: 8 KB 网页链接查看全文
持股变动声明
Allogene疗法(ALLO)03-17 05:12
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001737287-23-000024 Size: 6 KB 网页链接查看全文
持股变动声明
Allogene疗法(ALLO)03-17 04:57
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001593968-23-000492 Size: 5 KB 网页链接查看全文
持股变动声明
Allogene疗法(ALLO)03-17 04:51
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001593968-23-000491 Size: 5 KB 网页链接查看全文
当期报告
Allogene疗法(ALLO)03-11 05:06
$Allogene疗法(ALLO)$ 8-K Current report, item 7.01 Accession Number: 0001737287-23-000023 Act: 34 Size: 165 KB 网页链接查看全文
员工持股计划
Allogene疗法(ALLO)03-01 05:36
$Allogene疗法(ALLO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001737287-23-000020 Act: 33 Size: 133 KB 网页链接查看全文
年度财报
Allogene疗法(ALLO)03-01 05:27
$Allogene疗法(ALLO)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001737287-23-000018 Act: 34 Size: 12 MB 网页链接查看全文
当期报告
Allogene疗法(ALLO)03-01 05:12
$Allogene疗法(ALLO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001737287-23-000017 Act: 34 Size: 267 KB 网页链接查看全文
持股变动声明
Allogene疗法(ALLO)02-15 06:18
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001593968-23-000317 Size: 4 KB 网页链接查看全文
超过5%股东持股披露「修订」
Allogene疗法(ALLO)02-14 05:36
$Allogene疗法(ALLO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-23-035914 Act: 34 Size: 93 KB 网页链接查看全文
Allogene疗法的公告
持股变动声明
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001737287-23-000025 Size: 8 KB 网页链接
持股变动声明
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001737287-23-000024 Size: 6 KB 网页链接
持股变动声明
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001593968-23-000492 Size: 5 KB 网页链接
持股变动声明
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001593968-23-000491 Size: 5 KB 网页链接
当期报告
$Allogene疗法(ALLO)$ 8-K Current report, item 7.01 Accession Number: 0001737287-23-000023 Act: 34 Size: 165 KB 网页链接
员工持股计划
$Allogene疗法(ALLO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001737287-23-000020 Act: 33 Size: 133 KB 网页链接
年度财报
$Allogene疗法(ALLO)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001737287-23-000018 Act: 34 Size: 12 MB 网页链接
当期报告
$Allogene疗法(ALLO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001737287-23-000017 Act: 34 Size: 267 KB 网页链接
持股变动声明
$Allogene疗法(ALLO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001593968-23-000317 Size: 4 KB 网页链接
超过5%股东持股披露「修订」
$Allogene疗法(ALLO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-23-035914 Act: 34 Size: 93 KB 网页链接